Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Richard D. Carvajal, Paul Nathan, Joseph J. Sacco, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 17, pp. 1939-1948
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Advances in the clinical management of uveal melanoma
Richard D. Carvajal, Joseph J. Sacco, Martine J. Jager, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 99-115
Closed Access | Times Cited: 136
T-cell-engaging bispecific antibodies in cancer
Niels W.C.J. van de Donk, Sonja Zweegman
The Lancet (2023) Vol. 402, Iss. 10396, pp. 142-158
Closed Access | Times Cited: 123
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy A. Chan
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 604-623
Closed Access | Times Cited: 115
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2364-2373
Open Access | Times Cited: 102
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2256-2266
Open Access | Times Cited: 98
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 7, pp. 471-486
Closed Access | Times Cited: 67
Recent Advances and Challenges in Uveal Melanoma Immunotherapy
Yihang Fu, Wei Xiao, Yuxiang Mao
Cancers (2022) Vol. 14, Iss. 13, pp. 3094-3094
Open Access | Times Cited: 43
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 39
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Sarah Howlett, Thomas J. Carter, Heather M. Shaw, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 32
Uveal melanoma: In the era of new treatments
Mylène Wespiser, Ève-Marie Neidhardt, Sylvie Négrier
Cancer Treatment Reviews (2023) Vol. 119, pp. 102599-102599
Closed Access | Times Cited: 23
Uveal melanoma: Current evidence on prognosis, treatment and potential developments
Maria C. Gelmi, Martine J. Jager
Asia-Pacific Journal of Ophthalmology (2024) Vol. 13, Iss. 2, pp. 100060-100060
Open Access | Times Cited: 12
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Mohamed Shanshal, Paolo F. Caimi, Alex A. Adjei, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2824-2824
Open Access | Times Cited: 20
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
KyoungSoo Lim, Xu Zhu, Diansong Zhou, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 315-327
Open Access | Times Cited: 8
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J. Sacco, Richard D. Carvajal, Marcus O. Butler, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009028-e009028
Open Access | Times Cited: 6
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma
Robin Reschke, Alexander Enk, Jessica C. Hassel
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1046-1046
Open Access | Times Cited: 6
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma
Lanyi Nora Chen, Richard D. Carvajal
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 10, pp. 1017-1027
Open Access | Times Cited: 26
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
J. Weddell
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1726-1737
Open Access | Times Cited: 15
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Omid Hamid, Jessica C. Hassel, Alexander N. Shoushtari, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006747-e006747
Open Access | Times Cited: 15
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 15
Targeted therapy in ophthalmic oncology: The current status
Mrittika Sen, Hakan Demirci, Santosh G Honavar
Asia-Pacific Journal of Ophthalmology (2024) Vol. 13, Iss. 2, pp. 100062-100062
Open Access | Times Cited: 5
Updates in the Management of Uveal Melanoma
Mali Barbi, Richard D. Carvajal, Craig Devoe
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 92-101
Closed Access | Times Cited: 4
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
Mohamed Elmeliegy, Joseph Chen, Aruna Dontabhaktuni, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 637-646
Open Access | Times Cited: 4
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Catharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. e340-e351
Closed Access | Times Cited: 4
Adoptive T Cell Therapy Targeting MAGE-A4
Kapil Chandora, Akshay Chandora, Anwaar Saeed, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 413-413
Open Access
Unlocking the Promise of Antitumor Hyperthermia‐Immunotherapy with Spiky Surface Topology
Muyue Yang, Yan Yu, Tongxin Ge, et al.
Advanced Science (2025)
Open Access
Page 1 - Next Page

Scroll to top